Neeraj Agarwal: Consensus statement from 2024 United States Prostate Cancer Conference
Neeraj Agarwal, Professor of Medicine and Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, shared a post by Alan H Bryce, on X:
“Just in ACS Journal Cancer:
– Consensus statement from 2024 United States Prostate Cancer Conference (USPCC)
– Management of PSA recurrence, mHSPC, mCRPC, Rx with RLTs, PARPi & more (US perspective)
– open access.”
Authors: Alan H. Bryce, Neeraj Agarwal, Himisha Beltran, Maha H. Hussain, Oliver Sartor, Neal Shore, Emmanuel S. Antonarakis, Andrew J. Armstrong, Jeremie Calais, Michael A. Carducci, Tanya Barauskas Dorff, Jason A. Efstathiou, Martin Gleave, Leonard G. Gomella, Celestia Higano, Thomas A. Hope, Andrei Iagaru, Alicia K. Morgans, David S. Morris, Michael J. Morris, Daniel P. Petrylak, Robert E. Reiter, Matthew B. Rettig, Charles J. Ryan MD, Scott B. Sellinger, Daniel E. Spratt, Sandy Srinivas, Scott T. Tagawa, MS, Mary-Ellen Taplin, Evan Y. Yu, Tian Zhang, Rana R. McKay, Phillip J. Koo, E. David Crawford
Quoting Alan H Bryce‘s post:
“Very happy to share the manuscript from the 2024 United States Prostate Cancer Consensus Conference. Our goal with this is to address the many common clinical conundrums that occur daily in prostate cancer clinics but fall outside the areas covered by level 1 evidence.
The US represents a unique regulatory environment with a breadth of options for clinicians that is not present anywhere else, thus the choices faced by our practitioners are unique and we address many of them here. Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024 – Bryce – Cancer – Wiley Online Library.”
Neeraj Agarwal is a Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI. Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023